<DOC>
	<DOCNO>NCT02056392</DOCNO>
	<brief_summary>Study assess effect Selumetinib [ AZD6244 ; ARRY-142886 ] [ Hyd-Sulfate ] ) , QTc interval healthy male volunteer .</brief_summary>
	<brief_title>To Assess Effects Single Oral Dose Selumetinib AZD6244 ; ARRY-142886 Hyd-Sulfate ) , QTc Interval Healthy Male Volunteers</brief_title>
	<detailed_description>A double-blind ( Selumetinib [ AZD6244 ; ARRY-142886 ] [ Hyd-Sulfate ] ) , Placebo-controlled , Open-Label ( Moxifloxacin ) Positive-controlled , Randomized , Three-period Crossover Study Assess Effects Single Oral Dose Selumetinib ( 75 mg ) QTc Interval Compared Placebo , use AVELOX ( Moxifloxacin ) Positive Control , Healthy Male Volunteers</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Have body mass index ( BMI ) 18 30 kg/m2 weigh least 50 kg 100 kg ( inclusive ) . 2 . Must smoke last 30 day prior screen study . 3 . Have calculate creatinine clearance ( CrCL ) great 50 mL/min use CockcroftGault formula . 1 . Subjects Japanese nonJapanese Asian ethnicity . 2 . Subjects one parent grandparent ( maternal paternal ) Japanese nonJapanese Asian ( e.g . China , Taiwan , Korea , Philippines , Thailand , Vietnam , Malaysia ) . Asian Indians acceptable . 3 . Past history central serous retinopathy retinal vein thrombosis , intraocular pressure great 21 mmHg uncontrolled glaucoma . 4 . Any clinically relevant abnormal finding physical examination , hematology , clinical chemistry , urinalysis , vital sign ECG baseline opinion investigator . 5 . History presence clinically significant disease disorder opinion investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Phase I , healthy , pharmacokinetics</keyword>
</DOC>